Antiandrogenic therapy can cause coronary arterial disease

Kuan Chou Chen, Chiung Chi Peng, Hsiu Mei Hsieh, Chiung Huei Peng, Chiu-Lan Hsieh, Chien Ning Huang, Charng Cherng Chyau, Hui Er Wang, Robert Y. Peng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.

Original languageEnglish
Pages (from-to)886-891
Number of pages6
JournalInternational Journal of Urology
Volume12
Issue number10
DOIs
Publication statusPublished - 2005 Oct 1

Fingerprint

Cyproterone Acetate
Coronary Disease
Apolipoprotein A-II
Apolipoprotein A-I
Prostatic Neoplasms
Triglycerides
Apolipoprotein B-100
Androgen Antagonists
Neoplasm Grading
Therapeutics
Lipid Metabolism
HDL Cholesterol
Lipoproteins
Coronary Artery Disease
Estrogens
Radiotherapy
Cholesterol
Incidence

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Chen, K. C., Peng, C. C., Hsieh, H. M., Peng, C. H., Hsieh, C-L., Huang, C. N., ... Peng, R. Y. (2005). Antiandrogenic therapy can cause coronary arterial disease. International Journal of Urology, 12(10), 886-891. https://doi.org/10.1111/j.1442-2042.2005.01145.x
Chen, Kuan Chou ; Peng, Chiung Chi ; Hsieh, Hsiu Mei ; Peng, Chiung Huei ; Hsieh, Chiu-Lan ; Huang, Chien Ning ; Chyau, Charng Cherng ; Wang, Hui Er ; Peng, Robert Y. / Antiandrogenic therapy can cause coronary arterial disease. In: International Journal of Urology. 2005 ; Vol. 12, No. 10. pp. 886-891.
@article{75012fd861a7457e82c6c8f9ccd6cd34,
title = "Antiandrogenic therapy can cause coronary arterial disease",
abstract = "Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6{\%} as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.",
author = "Chen, {Kuan Chou} and Peng, {Chiung Chi} and Hsieh, {Hsiu Mei} and Peng, {Chiung Huei} and Chiu-Lan Hsieh and Huang, {Chien Ning} and Chyau, {Charng Cherng} and Wang, {Hui Er} and Peng, {Robert Y.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1111/j.1442-2042.2005.01145.x",
language = "English",
volume = "12",
pages = "886--891",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "10",

}

Chen, KC, Peng, CC, Hsieh, HM, Peng, CH, Hsieh, C-L, Huang, CN, Chyau, CC, Wang, HE & Peng, RY 2005, 'Antiandrogenic therapy can cause coronary arterial disease', International Journal of Urology, vol. 12, no. 10, pp. 886-891. https://doi.org/10.1111/j.1442-2042.2005.01145.x

Antiandrogenic therapy can cause coronary arterial disease. / Chen, Kuan Chou; Peng, Chiung Chi; Hsieh, Hsiu Mei; Peng, Chiung Huei; Hsieh, Chiu-Lan; Huang, Chien Ning; Chyau, Charng Cherng; Wang, Hui Er; Peng, Robert Y.

In: International Journal of Urology, Vol. 12, No. 10, 01.10.2005, p. 886-891.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antiandrogenic therapy can cause coronary arterial disease

AU - Chen, Kuan Chou

AU - Peng, Chiung Chi

AU - Hsieh, Hsiu Mei

AU - Peng, Chiung Huei

AU - Hsieh, Chiu-Lan

AU - Huang, Chien Ning

AU - Chyau, Charng Cherng

AU - Wang, Hui Er

AU - Peng, Robert Y.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.

AB - Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.

UR - http://www.scopus.com/inward/record.url?scp=28444464037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444464037&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2005.01145.x

DO - 10.1111/j.1442-2042.2005.01145.x

M3 - Article

VL - 12

SP - 886

EP - 891

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 10

ER -